文献速递真菌感染

Olorofim联合唑类抗真菌药:2期挽救治疗研究结果

Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

本研究基于一项2b期挽救治疗研究,评估Olorofim联合唑类抗真菌药对侵袭性真菌病患者的临床影响。结果显示,在第42天和第84天,联合或不联合唑类(无论是否具有抗霉菌活性)在MSG-EORTC应答和全因死亡率上表现相似,且联合唑类未增加药物性肝损伤发生率。结论提示未观察到联合用药降低疗效或耐受性的模式,但受样本量限制。

要点

  • Olorofim联合唑类(含氟康唑)未显示临床疗效降低。
  • 联合唑类未增加药物性肝损伤发生率。
  • 曲霉病患者中77例未联用唑类、24例联用,结局相似。

核心结论

  • 在2b期挽救治疗研究中,Olorofim联合唑类(无论是否具有抗霉菌活性或为氟康唑)未显示临床疗效或耐受性降低的模式。

研究设计与样本

  • 一项2b期挽救治疗研究,纳入侵袭性真菌病患者(治疗选择很少或无),比较Olorofim联合或不联合唑类的结局。
  • 曲霉病患者中77例未联用唑类、24例联用;球孢子菌病患者中11例未联用、30例联用;其他真菌感染患者中50例未联用、10例联用。

主要发现

  • 第42天(主要研究终点)和第84天,联合或不联合唑类在MSG-EORTC应答和全因死亡率上表现相似。
  • 药物性肝损伤发生率在联合唑类患者中未增加。

临床怎么用

  • 对于治疗选择有限的侵袭性真菌病患者,Olorofim可与唑类联合使用,未观察到疗效或耐受性降低的信号。

局限性

  • 分析受研究样本量限制,尤其针对个别真菌的患者数较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Olorofim is an antifungal agent with a novel mechanism of action against Aspergillus spp., rare moulds and dimorphic fungi. Preclinical studies reported unidirectional antagonism between olorofim and mould-active azoles (e.g. azoles other than fluconazole) against Aspergillus fumigatus in which the azole reduces the antifungal effect of olorofim. METHODS: To assess the potential clinical impact of this preclinical finding, we compared outcomes of olorofim with and without concomitant azoles from a Phase 2b salvage study in patients with invasive fungal diseases with few or no treatment options. RESULTS: Analyses are limited by the study size but outcomes were similar for olorofim with and without an azole in combination (whether mould-active or not) at Days 42 (the primary study endpoint) and 84 for both Mycoses Study Group-European Organization for Research and Treatment of Cancer (MSG-EORTC) responses and for all-cause mortality in patients with aspergillosis (77 not receiving an azole, 24 receiving an azole in combination), in patients with coccidioidomycosis (11 not receiving an azole, 30 receiving an azole in combination) and in patients with other fungal infections (50 not receiving an azole, 10 receiving an azole in combination). In addition, the rate of drug-induced liver injury was not increased in patients receiving combination with an azole. CONCLUSIONS: Although limited by small numbers of patients for individual fungi, this analysis did not demonstrate a pattern of reduced clinical efficacy or tolerability of olorofim when given in combination with either the mould-active azoles or with fluconazole.Trial registration number. NCT03583164.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Maertens J, Chen SCA, Thompson GR, et al. Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study. J Antimicrob Chemother. 2026. PMID: 41914555. doi:10.1093/jac/dkag118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。